Browse SDR16C5

Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF00106 short chain dehydrogenase
Function

Oxidoreductase with strong preference for NAD. Active in both the oxidative and reductive directions. Oxidizes all-trans-retinol in all-trans-retinaldehyde. No activity was detected with 11-cis-retinol or 11-cis-retinaldehyde as substrates with either NAD(+)/NADH or NADP(+)/NADPH.

> Gene Ontology
 
Biological Process GO:0001523 retinoid metabolic process
GO:0006066 alcohol metabolic process
GO:0006081 cellular aldehyde metabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0007601 visual perception
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009581 detection of external stimulus
GO:0009582 detection of abiotic stimulus
GO:0009583 detection of light stimulus
GO:0009584 detection of visible light
GO:0010817 regulation of hormone levels
GO:0016101 diterpenoid metabolic process
GO:0034308 primary alcohol metabolic process
GO:0034754 cellular hormone metabolic process
GO:0042445 hormone metabolic process
GO:0042572 retinol metabolic process
GO:0042574 retinal metabolic process
GO:0043616 keratinocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0050908 detection of light stimulus involved in visual perception
GO:0050953 sensory perception of light stimulus
GO:0050962 detection of light stimulus involved in sensory perception
GO:1901615 organic hydroxy compound metabolic process
Molecular Function GO:0004745 retinol dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00830 Retinol metabolism
Reactome R-HSA-5365859: RA biosynthesis pathway
R-HSA-162582: Signal Transduction
R-HSA-5362517: Signaling by Retinoic Acid
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SDR16C5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SDR16C5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SDR16C5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2470.641
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5550.533
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8370.27
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5660.491
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3780.756
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7960.562
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2130.838
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8380.609
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3690.84
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.830.0475
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SDR16C5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SDR16C5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SDR16C5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SDR16C5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SDR16C5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SDR16C5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SDR16C5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSDR16C5
Nameshort chain dehydrogenase/reductase family 16C, member 5
Aliases RDHE2; RDH#2; EPHD-2; epidermal retinal dehydrogenase 2; retinal short chain dehydrogenase reductase; retina ......
Chromosomal Location8q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SDR16C5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.